Oncomine Comprehensive Myeloid Panel Test
Short Name: Oncomine Myeloid Panel
Also known as: Oncomine Myeloid Panel, Myeloid Neoplasm Gene Panel, Comprehensive Myeloid Sequencing Panel, Myeloid Malignancy NGS Panel
Oncomine Comprehensive Myeloid Panel Test test available at DNA Labs India for ₹44,460. Uses Next-Generation Sequencing (NGS), Targeted Gene Panel Sequencing on Whole Blood or Bone Marrow samples. Results in Reports available by the 15th or 30th of the same month. Samples received by the 1st of the month will have reports by the 15th. Samples received by the 16th will have reports by the 30th. Total turnaround time is approximately 15–30 working days from sample receipt.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The primary purpose of the Oncomine Comprehensive Myeloid Panel Test is to identify somatic mutations and fusion genes in patients suspected of or diagnosed with myeloid neoplasms. The test aids in: (1) establishing a precise molecular diagnosis of myeloid malignancies; (2) risk stratification and prognostic assessment—for example, FLT3-ITD mutations in AML are associated with poorer prognosis; (3) identifying actionable mutations that guide targeted therapy selection; (4) monitoring minimal residual disease in some clinical contexts; and (5) supporting clinical trial enrollment decisions based on molecular profiling. The panel detects mutations in 41 genes for single nucleotide variants/indels (ABL1, ASXL1, BCOR, BAALC, BRAF, CALR, CEBPA, CBL, CSF3R, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MPL, MYD88, MYC, NPM1, NRAS, NF1, PTPN11, PHF6, PRPF8, RB1, RUNX1, SETBP1, SF3B1, SRSF2, SH2B3, SMC1A, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2) and over 29 fusion gene targets (ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, MLLT3, MLLT10, MECOM, MET, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3, TFE3).
- Test Code
- 1368
- CPT Code
- 81450
- ICD Code
- C92.9
- Price
- ₹44,460
- Sample Type
- Whole Blood or Bone Marrow
- Result Time
- Reports available by the 15th or 30th of the same month. Samples received by the 1st of the month will have reports by the 15th. Samples received by the 16th will have reports by the 30th. Total turnaround time is approximately 15–30 working days from sample receipt.
- Fasting Required
- No
- Method
- Next-Generation Sequencing (NGS), Targeted Gene Panel Sequencing
Sample Collection
Ensure the NGS Test Requisition Form (Form 40) is duly filled and signed by the referring physician. No fasting is required. Inform the laboratory about any recent blood transfusions (within the past 4 weeks), as this may affect results. Ensure patient identification details are accurately recorded.
Method: Venipuncture / Bone Marrow Aspiration
Laboratory Analysis
Collect 3 mL (minimum 2 mL) of whole blood by venipuncture using a Lavender top (EDTA) tube. Alternatively, a bone marrow aspirate sample may be collected in the same tube type by the treating haematologist/oncologist. Ensure proper mixing with anticoagulant by gentle inversion 8–10 times. Label the tube with patient details, date, and time of collection.
Report Delivery
Ship the sample under refrigerated conditions (2–8°C). Do NOT freeze the sample. Ensure the sample reaches the laboratory within 72 hours of collection (optimal stability at refrigerator temperature). Room temperature stability is up to 6 hours only. Retain the completed NGS Test Requisition Form (Form 40) with the sample.
Timeline: Reports available by the 15th or 30th of the same month. Samples received by the 1st of the month will have reports by the 15th. Samples received by the 16th will have reports by the 30th. Total turnaround time is approximately 15–30 working days from sample receipt.
Patient Instructions
About This Test
Who Should Get This Test
The primary purpose of the Oncomine Comprehensive Myeloid Panel Test is to identify somatic mutations and fusion genes in patients suspected of or diagnosed with myeloid neoplasms. The test aids in: (1) establishing a precise molecular diagnosis of myeloid malignancies; (2) risk stratification and prognostic assessment—for example, FLT3-ITD mutations in AML are associated with poorer prognosis; (3) identifying actionable mutations that guide targeted therapy selection; (4) monitoring minimal residual disease in some clinical contexts; and (5) supporting clinical trial enrollment decisions based on molecular profiling. The panel detects mutations in 41 genes for single nucleotide variants/indels (ABL1, ASXL1, BCOR, BAALC, BRAF, CALR, CEBPA, CBL, CSF3R, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MPL, MYD88, MYC, NPM1, NRAS, NF1, PTPN11, PHF6, PRPF8, RB1, RUNX1, SETBP1, SF3B1, SRSF2, SH2B3, SMC1A, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2) and over 29 fusion gene targets (ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, MLLT3, MLLT10, MECOM, MET, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3, TFE3).
How to Prepare
- Collect 3 mL (minimum 2 mL) whole blood or bone marrow in 1 Lavender top (EDTA) tube.
- Gently invert the tube 8–10 times to mix with anticoagulant. Do not shake.
- Label the tube clearly with patient name, date of birth, date and time of collection.
- Ship refrigerated (2–8°C). Do NOT freeze the sample.
- Include the duly filled NGS Test Requisition Form (Form 40) with the sample.
- Ensure the sample reaches the laboratory within 72 hours of collection.
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"The Oncomine Comprehensive Myeloid Panel is an invaluable tool in the diagnostic workup of myeloid neoplasms. Identifying mutations in genes such as FLT3, NPM1, TP53, ASXL1, and JAK2 not only aids in precise sub-classification of disease but also guides therapeutic decision-making—for example, determining eligibility for FLT3 inhibitors or predicting response to hypomethylating agents. This panel should be considered for all patients with newly diagnosed AML, MDS, or MPN where molecular profiling may influence treatment strategy or prognostic risk stratification."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Sample received frozen
- Sample collected in non-EDTA tube
- Hemolyzed or clotted sample
- Sample volume below minimum requirement (less than 2 mL)
- Missing or incomplete NGS Test Requisition Form (Form 40)
- Sample received at room temperature after 6 hours of collection
- Unlabelled or mislabelled sample
Understanding Your Results
All genes – Not Detected
May suggest absence of common myeloid driver mutations; further workup may still be indicated based on clinical suspicion.
FLT3-ITD Detected
Consider FLT3 inhibitor therapy (midostaurin, gilteritinib). Adverse prognostic marker in AML. FLT3-ITD allelic ratio is important for risk stratification.
NPM1 Mutation Detected
Favorable prognosis when present without concurrent FLT3-ITD. May be used for minimal residual disease monitoring.
TP53 Mutation Detected
Very poor prognosis across all myeloid malignancies. Associated with resistance to conventional chemotherapy. Consider clinical trials or novel agents.
JAK2 V617F Detected
Supports diagnosis of BCR-ABL1-negative myeloproliferative neoplasm. Eligible for JAK inhibitor therapy (ruxolitinib).
IDH1 or IDH2 Mutation Detected
Eligible for targeted IDH inhibitor therapy (ivosidenib for IDH1, enasidenib for IDH2). May also be relevant in MDS.
Fusion Gene Detected (e.g., KMT2A rearrangement)
May define a specific WHO subtype of AML or other myeloid neoplasm. May confer eligibility for targeted therapies or clinical trials. Important for risk stratification.
Splicing Factor Mutations (SF3B1, SRSF2, U2AF1, ZRSR2)
SF3B1 mutations are associated with ring sideroblasts and relatively favorable prognosis. SRSF2 and U2AF1 mutations carry adverse prognostic significance in MDS.
Consult your haematologist or oncologist if you are experiencing symptoms such as persistent fatigue, unexplained weakness, frequent infections, easy bruising or bleeding, shortness of breath, unexplained weight loss, or swollen lymph nodes. This test should be ordered by a qualified physician when there is clinical suspicion of a myeloid malignancy based on abnormal blood counts, peripheral smear findings, bone marrow examination, or prior laboratory results. After receiving test results, schedule a follow-up appointment with your treating specialist for comprehensive interpretation in the context of your overall clinical profile and to discuss treatment options.
Limitations
- ⚠This test detects mutations in the 57 targeted genes only; it does not cover the entire genome.
- ⚠Low-level mutations below the analytical sensitivity threshold of the NGS platform may not be detected.
- ⚠Copy number variations (large deletions/duplications) and loss of heterozygosity (LOH) may not be fully captured.
- ⚠Results should always be interpreted in conjunction with clinical findings, morphology, immunophenotyping, and cytogenetics.
- ⚠The test does not replace karyotyping or FISH for detection of large chromosomal abnormalities such as translocations or aneuploidies.
- ⚠Germline mutations may be detected incidentally; genetic counselling is recommended for interpretation.
Risks & Considerations
- ●Minimal risk associated with blood draw – slight bruising or soreness at the venipuncture site
- ●If bone marrow aspiration is performed, there may be localized pain, minor bleeding, or infection at the aspiration site
- ●Psychological impact of receiving genetic information – genetic counselling is recommended
- ●Incidental detection of germline variants with potential hereditary implications
Interfering Factors
- ●Sample stored at incorrect temperature (freezing is not acceptable)
- ●Insufficient sample volume (below 2 mL)
- ●Sample collected in incorrect anticoagulant (non-EDTA tube)
- ●Hemolyzed or clotted blood sample
- ●Prior blood transfusion within 4 weeks may dilute tumor DNA
- ●Incomplete or missing NGS Test Requisition Form (Form 40)
Compare With Similar Tests
| Test | Oncomine Comprehensive Myeloid Panel Test | FLT3 Mutation Analysis (Single Gene) | JAK2 V617F Mutation Test | Conventional Karyotyping | BCR-ABL1 Fusion (RT-PCR / FISH) |
|---|---|---|---|---|---|
| Comparison | Oncomine Comprehensive Myeloid Panel Test |
Frequently Asked Questions
What is the Oncomine Comprehensive Myeloid Panel Test?
What sample is required for this test?
What is the cost of the Oncomine Comprehensive Myeloid Panel Test at DNA Labs India?
Is fasting required before the test?
How long does it take to get the results?
Which genes are analyzed in this panel?
Who should get this test done?
What does it mean if all mutations are 'Not Detected'?
Is this test different from a routine blood test or CBC?
Can this test be done at home?
Do I need a doctor's prescription for this test?
Are the results of this test covered by health insurance?
Related Tests
Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.